Select Your Location:
Global
France
Switzerland DE | FR | IT

Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Disease State: Hematologic malignancies

Alessandra Tedeschi, Giorgio Minotti, Joe-Elie Salem, Stephan Stilgenbauer

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video
26 May 2025
Clemens Wendtner, Renata Walewska, Pier Luigi Zinzani, Matthew Davids

Overview of the treatment options for treatment naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and the use of BTKis in indolent lymphomas presented at the EHA2024 Hybrid Congress.

Video
26 May 2025

A global congress digest on targeted therapies in B-cell malignancies covering updates from recent studies presented at EHA2024.

Reading
26 May 2025
Please login or register to access the download

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

Slide-Kit
26 May 2025
Please login or register to access the download

Join Dr. Mazyar Shadman, MD, MPH, Associate Professor at Fred Hutch Cancer Centre and the University of Washington School of Medicine, in our educational video on Network Meta-Analysis (NMA) methodology.

Video
26 May 2025